The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial

A. Huijbers; Rob A.�E.�M. Tollenaar; Gabi W. van Pelt; Eliane C.M. Zeestraten; Susan Dutton; Christopher C. McConkey; Enric Domingo; Vincent T.H.B.M. Smit; Rachel Midgley; B F Warren; Elaine Johnstone; David Kerr; Wilma E. Mesker

doi:10.1093/annonc/mds246

Keywords

StromaMedicineHazard ratioColorectal cancerOncologyInternal medicineStage (stratigraphy)UrologyCancerGastroenterologyPathologyConfidence intervalImmunohistochemistryBiology

Affiliated Institutions

Related Publications

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Franck Pagès , Bernhard Mlecnik , Florence Marliot +96 more

The estimation of risk of recurrence for patients with colon carcinoma must be improved. A robust immune score quantification is needed to introduce immune parameters into cance...

2018 The Lancet 1944 citations

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

Bernhard Mlecnik , Marie Tosolini , Amos Kirilovsky +8 more

Purpose The prognosis of patients with colorectal cancer has sometimes proved uncertain; thus, the prognostic significance of immune criteria was compared with that of the tumor...

2011 Journal of Clinical Oncology 981 citations

The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage

Wilma E. Mesker , Jan M. C. Junggeburt , Károly Szuhai +4 more

Background : Tumor staging insufficiently discriminates between colon cancer patients with poor and better prognosis. We have evaluated, for the primary tumor, if the carcinoma‐...

2007 Analytical Cellular Pathology 347 citations

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

Michael A. Bookman , Mark F. Brady , William P. McGuire +13 more

Purpose To determine if incorporation of an additional cytotoxic agent improves overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelia...

2009 Journal of Clinical Oncology 696 citations

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

K. Kian Ang , Jonathan Harris , Richard Wheeler +12 more

Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)

2010 New England Journal of Medicine 6298 citations

Publication Info

Year: 2012
Type: article
Volume: 24
Issue: 1
Pages: 179-185
Citations: 333
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

333

OpenAlex

Cite This

APA Style

                            
                                
                                    A. Huijbers, 
                                
                                    Rob A.�E.�M. Tollenaar, 
                                
                                    Gabi W. van Pelt
                                
                                et al.
                            
                            (2012). 
                            The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. 
                            Annals of Oncology
                            , 24
                            (1)
                            , 179-185.
                            https://doi.org/10.1093/annonc/mds246
                        

Identifiers

DOI: 10.1093/annonc/mds246